International Immunopharmacology · 2022 · 22 citations · 24 references
MedicineOrthopaedic SurgeryPathobiologyAutophagyBone MetabolismInflammationAnti-inflammatory PharmacologyCartilage BreakdownInflammatory SignalingJoint DiseaseOsteoarthritisOsteoclast BiologyAcute Inflammatory ResponseBone Resorption InhibitionCartilage Breakdown PathophysiologyInflammatory Mediators In CartilageNecroptotic SignalingNf-κb SignalingOsteoclast InhibitionSubchondral Bone Inflammation
As a degenerative disease, the pathogenesis and treatment of osteoarthritis (OA) are still being studied. The prevailing view is that articular cartilage dysfunction plays an essential role in the development of osteoarthritis. Similarly, dynamic bone remodeling dramatically influences the development of osteoarthritis. The inflammatory response is caused by the overexpression of inflammatory factors, among which tumor necrosis factor-α is one of the main causes of OA, and its sources include the secretion of chondrocytes themselves and osteoclast secretion of subchondral bone. Moreover, TNF-α-induced activation of RIP1, RIP3, and MLKL has been shown to play an important role in cell necroptosis and inflammatory responses. In vitro, AZ-628 alleviates chondrocyte inflammation and necroptosis by inhibiting the NF-κB signaling pathway and RIP3 activation instead of RIP1 activation. AZ-628 also reduces osteoclast activity, proliferation and differentiation, and release of inflammatory substances by inhibiting autophagy, MAPK, and NF-κB pathways. Similarly, the in vivo study demonstrated that AZ-628 could inhibit chondrocyte breakdown and lower osteoclast formation and bone resorption, thereby slowing down subchondral bone changes induced by dynamic bone remodeling and reversing the progression of osteoarthritis in mice. The results of this study indicate that AZ-628 could be used to treat OA byinhibiting chondrocyte necroptosis and regulating osteoclast formation.
24
Jixi Li, Thomas J. McQuade, Ansgar B. Siemer et al. · Cell · 2012 · 1.2K citations · Full text
RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL
Kate E. Lawlor, Nufail Khan, Alison Mildenhall et al. · Nature Communications · 2015 · 641 citations · Full text
Life Sciences, Immunology, Pathology +17
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Clara Montagut, Sreenath V. Sharma, Toshi Shioda et al. · Cancer Research · 2008 · 504 citations · Full text
Medicine, Cancer Biology, Oncology +17